Inhibikase Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Inhibikase Therapeutics generated cash of -$18,085,043, which is less than the previous year. Cash used in financing activities reached the amount of $8,405,003 last year. Net change in cash is therefore $1,976,626.
Cash Flow
| 2017 | -126.39K | 0 | 131.02K |
|---|---|---|---|
| 2018 | 714.98K | 87.09K | -439.19K |
| 2019 | -338.29K | 0 | -22.81K |
| 2020 | -1.12M | 0 | 15.06M |
| 2021 | -14.29M | 0 | 41.09M |
| 2022 | -17.35M | -16.00M | -204.76K |
| 2023 | -18.08M | 11.65M | 8.40M |
IKT Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 7.18M | 40.75M | 13.95M | 18.45K | 379.55K | 16.66K | 12.03K |
Operating activities | |||||||
Net income | -19.02M | -18.05M | -14.78M | -2.84M | -5.72M | -2.15M | -436.07K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 177.39K | 6.72K | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 500.14K | 458.14K | 1.53M | 573.69K | 1.43M | 0 | 300.65K |
| Deferred income tax benefit | 500.14K | 458.14K | 1.53M | 573.69K | 1.43M | 0 | 300.65K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 39.88K | 70.25K | -110.14K | 0 | 472.94K | -292.16K | -113.90K |
Inventories | 0 | 0 | 1.30M | 0 | -54.89K | 950.65K | 0 |
Accounts payable | -504.40K | 61.39K | -630.90K | -247.07K | 47.46K | 600.71K | -78.27K |
Cash generated by operating activities | -18.08M | -17.35M | -14.29M | -1.12M | -338.29K | 714.98K | -126.39K |
Investing activities | |||||||
Purchases Of Investments | -29.42M | -20.72M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -14.23K | -243.25K | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 243.25K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 11.65M | -16.00M | 0 | 0 | 0 | 87.09K | 0 |
Financing activities | |||||||
Common Stock Issued | 8.54M | 0 | 41.21M | 14.79M | 0 | 1.18M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -77.65K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -248.91K | -42.53K | -272.8K | -22.81K | -26.31K | 0 |
Cash used in financing activities | 8.40M | -204.76K | 41.09M | 15.06M | -22.81K | -439.19K | 131.02K |
Net Change In Cash | 1.97M | -33.56M | 26.79M | 13.93M | -361.1K | 362.89K | 4.62K |
Cash at end of period | 9.16M | 7.18M | 40.75M | 13.95M | 18.45K | 379.55K | 16.66K |
| Data source | Data source | Data source | Data source |